Penumbra Inc is a medical technology company that specializes in the development and manufacturing of innovative devices for the treatment of various vascular and neurological conditions
The company focuses on creating solutions that are minimally invasive and designed to improve patient outcomes in areas such as stroke intervention, peripheral artery disease, and other critical health challenges. Penumbra leverages advanced engineering and regulatory expertise to offer state-of-the-art products that enhance the capabilities of healthcare professionals and provide better care for patients.
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Shares of medical device company Penumbra (NYSEPEN)
jumped 13.6% in the afternoon session after the company reported impressive fourth-quarter 2024 results, which blew past analysts' constant currency revenue, EBITDA, and earnings expectations. Sales grew by 10.8% compared to the previous year due to strong performance in its U.S. thrombectomy business, which surged 27.3%. This strength helped offset a 16.5% decline in international sales, largely due to weaker performance in China. However, despite the strong quarter, full-year revenue guidance for 2025 fell slightly short of expectations.
Looking ahead, the company expects continued growth in its U.S. thrombectomy business, particularly from its computer-assisted vacuum thrombectomy (CAVT) products. That said, international market softness remains a concern.
Penumbra stock climbs after Q4 earnings surpass expectations, with sales up 10.8% Y/Y. Analysts raise price targets as the company projects strong 2025 growth.
Medical device company Penumbra (NYSEPEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.8% year on year to $315.5 million. On the other hand, the company’s full-year revenue guidance of $1.35 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $0.97 per share was 8.5% above analysts’ consensus estimates.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSEAORT) and its peers.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including ICU Medical (NASDAQICUI) and its peers.
Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Penumbra (NYSEPEN) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Merit Medical Systems (NASDAQMMSI) and its peers.
